180 related articles for article (PubMed ID: 27386791)
21. Tuning aerosol performance using the multibreath Orbital® dry powder inhaler device: controlling delivery parameters and aerosol performance via modification of puck orifice geometry.
Zhu B; Young PM; Ong HX; Crapper J; Flodin C; Qiao EL; Phillips G; Traini D
J Pharm Sci; 2015 Jul; 104(7):2169-76. PubMed ID: 25931324
[TBL] [Abstract][Full Text] [Related]
22. Modeling the performance of carrier-based dry powder inhalation formulations: Where are we, and how to get there?
Elsayed MMA; Shalash AO
J Control Release; 2018 Jun; 279():251-261. PubMed ID: 29574042
[TBL] [Abstract][Full Text] [Related]
23. Dry powder inhalers: An overview of the in vitro dissolution methodologies and their correlation with the biopharmaceutical aspects of the drug products.
Velaga SP; Djuris J; Cvijic S; Rozou S; Russo P; Colombo G; Rossi A
Eur J Pharm Sci; 2018 Feb; 113():18-28. PubMed ID: 28887232
[TBL] [Abstract][Full Text] [Related]
24. Alternative carriers in dry powder inhaler formulations.
Rahimpour Y; Kouhsoltani M; Hamishehkar H
Drug Discov Today; 2014 May; 19(5):618-26. PubMed ID: 24269834
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the cohesion-adhesion balance approach to colloidal probe atomic force microscopy and the measurement of Hansen partial solubility parameters by inverse gas chromatography for the prediction of dry powder inhalation performance.
Jones MD; Buckton G
Int J Pharm; 2016 Jul; 509(1-2):419-430. PubMed ID: 27265314
[TBL] [Abstract][Full Text] [Related]
26. Single step spray drying method to develop proliposomes for inhalation: a systematic study based on quality by design approach.
Patil-Gadhe A; Pokharkar V
Pulm Pharmacol Ther; 2014 Apr; 27(2):197-207. PubMed ID: 23916767
[TBL] [Abstract][Full Text] [Related]
27. Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections.
Vandenheuvel D; Singh A; Vandersteegen K; Klumpp J; Lavigne R; Van den Mooter G
Eur J Pharm Biopharm; 2013 Aug; 84(3):578-82. PubMed ID: 23353012
[TBL] [Abstract][Full Text] [Related]
28. Spray freeze drying for dry powder inhalation of nanoparticles.
Ali ME; Lamprecht A
Eur J Pharm Biopharm; 2014 Aug; 87(3):510-7. PubMed ID: 24657824
[TBL] [Abstract][Full Text] [Related]
29. Suitability of differently formulated dry powder Newcastle disease vaccines for mass vaccination of poultry.
Huyge K; Van Reeth K; De Beer T; Landman WJ; van Eck JH; Remon JP; Vervaet C
Eur J Pharm Biopharm; 2012 Apr; 80(3):649-56. PubMed ID: 22155763
[TBL] [Abstract][Full Text] [Related]
30. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
Li X; Vogt FG; Hayes D; Mansour HM
Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
[TBL] [Abstract][Full Text] [Related]
31. Formulation strategy and use of excipients in pulmonary drug delivery.
Pilcer G; Amighi K
Int J Pharm; 2010 Jun; 392(1-2):1-19. PubMed ID: 20223286
[TBL] [Abstract][Full Text] [Related]
32. Quality assurance test of delivered dose uniformity of multiple-dose inhaler and dry powder inhaler drug products.
Tsong Y; Dong X; Shen M; Lostritto RT
J Biopharm Stat; 2015; 25(2):328-38. PubMed ID: 25357132
[TBL] [Abstract][Full Text] [Related]
33. From single excipients to dual excipient platforms in dry powder inhaler products.
Shur J; Price R; Lewis D; Young PM; Woollam G; Singh D; Edge S
Int J Pharm; 2016 Dec; 514(2):374-383. PubMed ID: 27262269
[TBL] [Abstract][Full Text] [Related]
34. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
Le VN; Robins E; Flament MP
Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
[TBL] [Abstract][Full Text] [Related]
35. Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation.
Fabio K; Curley K; Guarneri J; Adamo B; Laurenzi B; Grant M; Offord R; Kraft K; Leone-Bay A
AAPS PharmSciTech; 2015 Dec; 16(6):1299-306. PubMed ID: 25776985
[TBL] [Abstract][Full Text] [Related]
36. Quality by design (QbD) approaches in current pharmaceutical set-up.
Mishra V; Thakur S; Patil A; Shukla A
Expert Opin Drug Deliv; 2018 Aug; 15(8):737-758. PubMed ID: 30044646
[TBL] [Abstract][Full Text] [Related]
37. Orally inhaled drug performance testing for product development, registration, and quality control.
Lastow O; Svensson M
J Aerosol Med Pulm Drug Deliv; 2014 Dec; 27(6):401-7. PubMed ID: 25237712
[TBL] [Abstract][Full Text] [Related]
38. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease.
Adi H; Young PM; Chan HK; Agus H; Traini D
Eur J Pharm Sci; 2010 Jun; 40(3):239-47. PubMed ID: 20371286
[TBL] [Abstract][Full Text] [Related]
39. Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties.
Duret C; Wauthoz N; Sebti T; Vanderbist F; Amighi K
Int J Pharm; 2012 May; 428(1-2):103-13. PubMed ID: 22414388
[TBL] [Abstract][Full Text] [Related]
40. Redispersible liposomal-N-acetylcysteine powder for pulmonary administration: development, in vitro characterization and antioxidant activity.
Ourique AF; Chaves Pdos S; Souto GD; Pohlmann AR; Guterres SS; Beck RC
Eur J Pharm Sci; 2014 Dec; 65():174-82. PubMed ID: 25263567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
